Vivesto Ab · OMXSTO:VIVE
Vivesto Ab — Oasmia Pharmaceutical — Q3 2021 Earnings Presentation
18 slides from Vivesto Ab's earnings presentation, Nov 18, 2021
Slide 1: Q3 Results (1 Jan – 30 Sep 2021)
Q3 RESULTS (1 JAN – 30 SEP 2021) Francois Martelet M.D., CEO and Fredrik Järrsten, CFO 18th November 2021 1
Slide 2: Forward-looking statement
Forward-looking statement IMPORTANT NOTICE The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require p
Slide 3: Today's speakers
Today’s speakers FRANCOIS MARTELET, M.D. FREDRIK JÄRRSTEN Chief Executive Officer Chief Finance Officer 3
Slide 4: Transforming Oasmia since March 2020
Transforming Oasmia since March 2020 Rightsizing Putting our finances in Building Reducing the company order the in-house business risks, including and terminating by eliminating capabilities resolving inherited legal commercial drug unnecessary operating to make us an attractive issues production e
Slide 5: Our mission
Our mission To build a diversified pipeline focused on hard-to-treat and late-stage cancers using different mechanisms of action 5
Slide 6: Pursuing relentlessly our growth strategy while maximizing existing assets
Pursuing relentlessly our growth strategy while maximizing existing assets Oncology R&D: in-licensed & wholly-owned development-stage assets: • Cantrixil • Docetaxel Micellar • String-of-pearls strategy to build a diversified pipeline focused on hard-to-treat cancers Commercial: revenues from out-li
Slide 7: Sustaining our transformation in Q3 2021
Sustaining our transformation in Q3 2021 • Building our capabilities – experienced Heads of Clinical Development & Regulatory Affairs appointed • Maximizing Apealea ‒ License agreement with FarmaMondo in Russia & CIS ‒ Inceptua planning to launch in selected countries (Germany, UK) in 2022 as a firs
Slide 8: Strengthening our in-house capabilities to build a diversified oncology pipeline
Strengthening our in-house capabilities to build a diversified oncology pipeline Business Partnering Pipeline Regulatory Clinical Product Development Development Francois Martelet, MD Fredrik Järrsten Dr Heidi B Ramstad Reinhard Koenig, MD Peter Selin, BSc Kia Bengtsson Johanna Röstin Chief Executiv
Slide 9: Maximizing Apealea commercial potential through partners
Maximizing Apealea commercial potential through partners Russia / CIS Europe Commercialisation agreement signed with FarmaMondo USA Preparations for potential • Elevar reviewing optimal launch in early 2022 in regulatory & commercial pathway selected territories 9 1 Rx Securities and Edison
Slide 10: Driving our pipeline – Cantrixil Phase 2 preparations
Driving our pipeline – Cantrixil Phase 2 preparations • First product in our string-of-pearls strategy in-licensed in March 2021 • First-in-class tubulin-binding small molecule with potent cytotoxicity against CD 44+ ovarian cancer stem cells, ovarian somatic cancer cells (CD 44+), both resistant to
Slide 11: Driving our current pipeline – Phase 1b in prostate cancer on track
Driving our current pipeline – Phase 1b in prostate cancer on track • Phase 1b trial with SAKK - Swiss Group for Clinical Cancer Research ‒ Open-label, multicenter, single-stage trial at major hospitals in Switzerland 1 ‒ Recruiting 18 chemotherapy-naïve patients with metastatic castration resistant
Slide 12: Research with Karolinska Institutet
Research with Karolinska Institutet • Evaluation of the biological interactions of XR-17 platform with cellular systems in-vitro • Objective to expand our understanding of XR-17 and evaluate future applications for active pharmaceutical ingredients (APIs) • Research began in H1 2021 on cellular mech
Slide 13: Becoming an attractive partner for innovative oncology assets and companies
Becoming an attractive partner for innovative oncology assets and companies • Comprehensive in-house Building a Business multi-MoA capabilities in place portfolio Development • Opportunity to build diversified portfolio with Product multiple MoA and shots Development Partnering on goal • Working clo
Slide 14: Business development and licensing progress during the quarter
Business development and licensing progress during the quarter • Our ‘string of pearls’ approach to build critical mass ‒ Leveraging our Development, Regulatory & Commerical Partnering skills ‒ Evaluating a wide range of targets with multiple MoA (pre-clinical to late Phase 3) ‒ Potential for high v
Slide 15: Settling outstanding inherited disputes is reducing business risk
Settling outstanding inherited disputes is reducing business risk • Global settlement announced post-period end addresses all disputes with MGC Capital, former Board Members of Oasmia and members of former management • Settlement will result in a negative cashflow effect of MSEK 24.5 but with a posi
Slide 16: Q3 financial results – continued reduction in cash burn
Q3 financial results – continued reduction in cash burn Significant reduction in Opex (MSEK) Q3 2021 Q2 2021 Q3 2020 Q2 2020 • 0,0 Net sales of MSEK 11.9 -10,0 ‒ Drug products shipped to Elevar -20,0 • Operating costs totalled MSEK 26.4 -30,0 -26.4 -32.1 ‒ Further reduction since Q2, implying annual
Slide 17: Building a global oncology business – multiple catalysts to drive value in 2022
Building a global oncology business – multiple catalysts to drive value in 2022 Potential near- and mid-term value drivers • Sustained M&A & in-licensing to build critical mass in oncology • Cantrixil – preparation for Phase 2 initiation • Docetaxel micellar – Phase 1b completion of enrolment • XR-1
Slide 18: Thank you!
Thank you! Oasmia Pharmaceutical AB (STO: OASM) +46 018-50 54 40 www.linkedin.com/comp Vallongatan 1 any/oasmia- 752 28 Uppsala IR@oasmia.com pharmaceutical-ab Sweden www.oasmia.com www.twitter.com/Oasmia
Oasmia Pharmaceutical — Q3 2021 Earnings Presentation on 6ix